1. Introduction {#sec1}
===============

Nowadays, foods that are palatable to most individuals are those high in fat, especially saturated fat. A high-fat diet (HFD) leads to the expansion of adipose tissue and abdominal obesity, which are associated with metabolic abnormalities including complex and chronic cardiovascular disease, liver disorders, and others [@bib1], [@bib2]. In particular, cardiovascular disease is considered a serious public health issue globally and is among the top five causes of death in most countries [@bib1], [@bib3]. Cardiovascular disease causes up to 17 million deaths every year and results from thrombosis, atherosclerosis, and myocardial infarction [@bib4].

Hyperlipidemia is accompanied by platelet hyperactivity, hypercoagulability, and hypofibrinolysis, and plays a key role in the pathogenesis of cardiovascular diseases such as atherosclerosis [@bib5], [@bib6]. The major pathological pathway involved in these disorders is the development of an occlusive thrombus in the arteries. Collapses of atherosclerotic plaques by rupture or erosion leads to prothrombotic conditions involving circulating platelets and procoagulant factors. The main thrombotic elements related to atherosclerotic plaques are tissue factor and collagen [@bib7]. These result in platelet aggregation and activation to induce cardiovascular disease [@bib8]. Because studies on the regulation of platelet hyperactivity have focused on approaches to prevent thrombosis, many therapies aimed at suppressing platelet function have been developed [@bib8], [@bib9]. Moreover, for alternative treatments, numerous patients and healthcare specialists have sought oriental medicines or herbal remedies with potential effectiveness and without side effects such as gastrointestinal side effects, hemorrhage, and decreased platelets counts [@bib1], [@bib8].

Among the natural product alternative treatments, ginseng and its related components have been widely used for thousands of years, either in food or herbal medicines, to treat various diseases. Ginseng has antiaging, antidiabetic, anticarcinogenic, and antifatigue functions through the promotion of DNA, RNA, and protein synthesis [@bib10]. In addition, ginseng has been classified into 11 different species and contains approximately 200 ingredients, including ginsenosides, polysaccharides, polyacetylenes, fatty acids, mineral oils, peptides, and amino acids [@bib11].

In particular, the bioactivity of ginseng results from the presence of ginsenosides in its roots [@bib8]. Thus, until now, many studies have focused on the effect of the ginseng root [@bib12]. However, these active ingredients are also distributed in other parts of the ginseng plant, such as the berries and leaves. Current studies have reported that the ginseng berry (GB) has higher ginsenoside content than that of the root and may exert more pharmacological effects on various diseases via its antihyperglycemic and antiobesity activities [@bib6], [@bib13]. Moreover, the harvesting of GB is easier than that of the root because it can be harvested several times after the 3^rd^ yr of growth, whereas the root is only harvested between the 4^th^ and 6^th^ yr of growth [@bib14]. However, until now, GB has not received much attention [@bib6].

Consumption of a HFD, which includes foods palatable to many individuals, induces cardiovascular disease through alterations in lipid metabolism and blood coagulation, for which treatments with potential effectiveness and without various side effects are needed. GB contains a high ginsenoside content, which might exert pharmacological effects on cardiovascular diseases. However, there have been no reports regarding GB. Therefore, the purpose of the present study was to investigate the possibility of GB as a putative agent to improve blood flow in rats fed a HFD.

2. Materials and methods {#sec2}
========================

2.1. Animals and experimental diets {#sec2.1}
-----------------------------------

The animals used in this study were 5-wk-old male Sprague Dawley rats (140 ± 6.00 g) purchased from Central Lab. Animal Inc. (Seoul, Korea) and acclimatized for 1 wk. Each cage contained two rats. Rats were exposed to a 12-h light/dark cycle and maintained at a constant temperature of 22 ± 2°C and 55 ± 5% humidity. All animals were fed for 12 wk. The rats were selected randomly and assigned to five groups (12 rats/group). One group served as the control (CON) and was fed a normal diet (Zeigler Bros, Gardners, PA, USA). The other four groups were fed a HFD (D12451; Research Diets Inc., New Brunswick, NJ, USA) containing 45% kcal from fat for 11 wk without GB. Three of the HFD groups were additionally treated by gastric gavage with GB hot water extract (GBx) dissolved in distilled water at 50 (GBx 50) mg/kg, 100 (GBx 100) mg/kg, and 150 (GBx 150) mg/kg body weight for 6 wk ([Fig. 1](#fig1){ref-type="fig"}). This study was approved (EUIACUC 15-06) by the Eulji University Institutional Animal Care and Use Committee.

2.2. Preparation of GBx {#sec2.2}
-----------------------

GB was extracted in three volumes of distilled water in a shaking incubator at 80°C for 10 h. The extract was filtered through a 60-mesh sieve filter and concentrated into a dry solid using a rotary vacuum evaporator (Daesung Machinery Co., Chuncheon, Korea) at 60°C, up to a 25% soluble solid content, depending on the GB ingredient. For freeze drying, extracts were frozen overnight at −40°C and lyophilized using a freeze dryer (PVTFA 10AT; Inshin Lab. Co. Ltd., Seoul, Korea) for 3 d. GB powder was obtained after drying for 12 h at 60°C, and the final dried extract was stored at −20°C until use. Constituents of the GBx were analyzed using HPLC. HPLC analysis of GB extract powder was done using an Agilent HPLC system (Agilent Technologies., Santa Clara, CA, USA) equipped with a binary pump and diode array detector. An aqueous solution of test materials (0.08 mg/mL) was injected at 10 μL. Separation was then done on a 5-μm Hector-M C18 column (4.6 mm × 250 mm; RS Tech Co., Daejeon, Korea). The mobile phase consisted of deionized water (A) and acetonitrile (B). The gradient was programmed as follows: 0--5 min: 20% B. 5--35 min: a linear gradient from 20% to 40% B; 35--45 min: 40% B. 45--45.1 min: a linear gradient from 40% to 20% B; 45.1--50 min: 20% B. The flow rate was 1.0  mL /min. The UV detector was set at 203 nm. Determination of major ginsenosides in the GB extract is shown in [Fig. 2](#fig2){ref-type="fig"}.

2.3. Biochemical metabolite assay {#sec2.3}
---------------------------------

Leptin (R&D Systems, Minneapolis, MN, USA) and adiponectin (Shibayagi Co. Ltd., Gunma, Japan) were measured using a commercial enzyme-linked immunosorbent assay kit. Apolipoproteins (apo) A, B100, and E, thromboxane A~2~, serotonin, and fibrinogen degradation products (FDP) were also measured using enzyme-linked immunosorbent assay kits (Elabscience Biotechnology Co. Ltd., Wuhan, China). After centrifugation, serum samples were mixed with substrate buffer and manganese solution and incubated for 2 h at 37°C, followed by further incubation with urea reagent at room temperature for another 30 min. Optical density was determined at 450 nm using a spectrophotometer.

2.4. Coagulation assays {#sec2.4}
-----------------------

Plasma for the coagulation assays was obtained by centrifugation (3,000 rpm, 10 min). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were measured within 2 h of sample collection using automated coagulation analyzers (Diagnostica Stago, Asnières, France) according to the manufacturer\'s instructions.

2.5. Platelet function assays {#sec2.5}
-----------------------------

The platelet function analyzer INNOVANCE PFA-200 *in-vitro* diagnostic system (Siemens Medical Solutions, Malvern, PA, USA) incorporates a high-shear flow system to simulate the *in vivo* hemodynamic conditions of platelet adhesion and aggregation as encountered at the site of a vascular lesion. The test has proved to be more sensitive than the template bleeding time [@bib15]. Blood samples were collected in vacutainers containing 3.2% buffered sodium citrate. We measured the closure time using both collagen/epinephrine (Col/EPI) and collagen/adenosine-5-diphosphate (Col/ADP) cartridges for every blood sample. Col/EPI and Col/ADP analyses were run on a Siemens INNOVANCE PFA-200 analyzer.

2.6. Histological analysis {#sec2.6}
--------------------------

Regular parts of individual liver and aortic tissues were separated and fixed in 10% neutral buffered formalin. After embedding in paraffin, 3--4-μm serial sections were prepared. Representative sections were stained with Hematoxylin and Eosin (H&E) for examination using light microscopy. After the histological profiles of individual organs were examined, alternatively, portions of liver that had been dehydrated in 30% sucrose solutions were cryostat sectioned for Oil red (OR) staining. To observe more detailed histopathological changes, the areas of steatohepatitis and the mean hepatocyte diameters were calculated by automated image analysis using i-Solution FL version 9.1 (IMT i-Solution Inc., Vancouver, Quebec, Canada) on the restricted view fields according to previous methods [@bib16], [@bib17]. Steatohepatitis regions, the percentage of fatty deposited regions in hepatic parenchyma as lipid deposited regions in restricted histological view field of liver (%/mm^2^ hepatic parenchyma), and the number of ballooning/lipid droplet-deposited hepatocytes (per 1,000 hepatocytes) around centrilobular regions were calculated using a cryostat and OR staining. The mean diameters of hepatocytes from H&E-stained, paraffin-embedded tissues were also calculated (μm) in restricted fields of view on a computer monitor using automated image analysis; at least 10 hepatocytes in each view field per liver were considered. In addition, to show more detailed histomorphometric changes, the mean diameters of the total aortic wall, tunica intima, and tunica media (μm/vessel) were measured using H&E staining, and the percentages of areas showing lipid deposition (%/mm^2^ aorta parenchyma) and atherosclerotic plaques (%/mm aortic surface) were measured using OR staining. The histopathologist was blinded to the group distribution during the analyses. One histological field in each prepared liver and aortic tissue specimen was analyzed; consequently, 12 liver and aortic histological fields per group were considered for further histomorphometric analysis.

2.7. Statistical analysis {#sec2.7}
-------------------------

Results are expressed as the means ± standard deviation. Statistical analyses were conducted using SPSS for Windows (Release 18.0K; SPSS Inc., Chicago, IL, USA). Results were analyzed by one-way analysis of variance. When a significant difference was detected, Fisher\'s least significant difference test for multiple comparisons was performed to determine significant differences among the groups.

3. Results {#sec3}
==========

3.1. Effect of GBx supplementation on lipid metabolites in rats fed a HFD {#sec3.1}
-------------------------------------------------------------------------

The effect of GBx on serum levels of lipid metabolites, including leptin, apoE, apoB/A, and adiponectin, were investigated in each group of rats. As shown in [Table 1](#tbl1){ref-type="table"}, while leptin levels in the HFD group were higher than those of the CON group, GBx (GBx 100 and GBx 150) significantly attenuated the HFD-induced increase in serum leptin levels (*p* \< 0.05). GBx treatment significantly increased apoE levels in a dose-dependent manner (*p* \< 0.05). ApoB/A levels were significantly lower in all three GBx groups compared with the CON and HFD groups (*p* \< 0.05). Adiponectin levels were significantly higher in all GBx-treated groups compared with the HFD group (*p* \< 0.05), and this effect was dose-dependent. Moreover, treatment with GBx 150 mg/kg induced almost a fourfold increase in adiponectin levels compared with rats fed a HFD only (*p* \< 0.05). In addition, histological analysis of the liver was performed. As shown in [Fig. 3](#fig3){ref-type="fig"}, in the HFD group, noticeable steatohepatitis was induced due to the deposition of lipid droplets and related severe hypertrophic changes, including increases in hepatocyte size, steatohepatitis area, number of ballooning hepatocytes, and mean hepatocyte diameters. However, GBx treatment improved the HFD-induced steatohepatitis and related hypertrophic changes ([Fig. 3](#fig3){ref-type="fig"}).

3.2. Effect of GBx supplementation on blood coagulation and platelet function in rats fed a HFD {#sec3.2}
-----------------------------------------------------------------------------------------------

Blood coagulation factors related to platelet function, including PT, aPTT, Col/EPI, and Col/ADP, were measured. As shown in [Table 2](#tbl2){ref-type="table"}, PT values were increased significantly in all GBx groups, and the aPTT levels were increased compared with the HFD group (*p* \< 0.05). However, there were no significant differences in Col/ADP or Col/EPI among the groups. The serum levels of thromboxane A~2~ (TXA~2~), serotonin, and FDP were also measured. In the GBx 100 and 150 groups, the serum levels of TXA~2~ were decreased significantly compared with the HFD group (*p* \< 0.05). In addition, whereas the serum levels of serotonin were increased in the HFD group compared with the CON group, the GBx 150 group showed significantly lower serum serotonin levels compared with the CON and HFD groups (*p* \< 0.05). The GBx 100 and 150 treatment groups also showed significantly higher serum FDP concentrations than those of the other groups (*p* \< 0.05). These results indicate that GBx is involved in the regulation of blood coagulation, suggesting GBx as a possible agent for blood coagulation-related disorders.

3.3. Effect of GBx supplementation on aortic tissues of rats fed a HFD {#sec3.3}
----------------------------------------------------------------------

Histomorphometric analysis showed severe hypertrophic changes in the walls of the aorta and formation of atherosclerotic plaques induced by a HFD ([Fig. 4](#fig4){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). In addition, significant increases in the mean thicknesses of the total aortic wall, tunica intima, and tunica media and in the areas of lipid deposition in the aortic wall and atherosclerotic plaques were induced compared with the CON group. However, these histomorphometric dyslipidemia-related atherosclerotic changes were significantly improved by treatment with GBx 50 mg/kg, 100 mg/kg, and 150 mg/kg in a dose-dependent manner (*p* \< 0.05).

4. Discussion {#sec4}
=============

A HFD induces cardiovascular disease through alterations in lipid metabolism and blood coagulation. GBx includes a high content of ginsenosides, which might exert pharmacological effects on cardiovascular disease. Therefore, the present study aimed to investigate the effect of GBx on blood flow in rats fed a HFD.

A HFD induces abnormalities in serum and hepatic lipid profiles [@bib1]. To evaluate risk factors for obesity, insulin resistance, and diabetes, as well as liver disorders, apoA, apoB, leptin, adiponectin, free fatty acids, ghrelin, and tumor necrosis factor-alpha were proposed as biomarkers [@bib18]. Therefore, to investigate the effect of GBx on lipid metabolites in this study, serum levels of leptin, apoE, apoB/A, and adiponectin were measured in each group of rats.

Leptin is a proteohormone that functions in the regulation of energy balance and body weight according to energy expenditure and is synthesized by differentiated adipocytes. Leptin levels are reportedly higher in obese individuals with nonalcoholic fatty liver disease [@bib18], [@bib19]. Similarly, in the present study, leptin levels in the HFD group were higher than those in the CON group, and GBx treatment significantly attenuated the HFD-induced increase in serum leptin levels. In addition, adiponectin, which is synthesized only by adipocytes, influences hepatocellular free fatty acid metabolism. Low levels of adiponectin have been linked to cardiovascular disease, considering that adiponectin potentially protects against cardiovascular disease by accumulating in injured vessel walls and acting as an antiatherogenic factor [@bib5]. In our study, we found that adiponectin levels in all three GBx groups were significantly higher than those in the HFD group, and this effect was dose-dependent. Previous studies reported increased leptin levels and decreased adiponectin levels in patients with steatosis and steatohepatitis due to morbid obesity [@bib18], [@bib20]. These findings are similar to our histological results showing evident steatohepatitis, induced by lipid droplet deposition, and related severe hypertrophic changes, including increased hepatocyte size, areas of steatohepatitis, number of ballooning hepatocytes, and mean hepatocyte diameters, in the HFD group. However, GBx treatment improved these liver impairments in a dose-dependent manner. Therefore, these results indicate that GBx ameliorates lipid-metabolite regulation as well as steatosis and steatohepatitis, with antagonizing effects against HFD-induced serum lipid profile and hepatic lipid distribution abnormalities.

Meanwhile, our results showed that apoE levels increased significantly in a dose-dependent manner with GBx treatment, whereas they were decreased in the HFD group. The decrease in apoE levels may be related to the development of atherosclerotic plaques [@bib21]. In addition, several studies have reported that adipocyte-derived hormones induced by HFD, including leptin, adiponectin, and apo, could be prominent regulators linking obesity and cardiovascular disease, since they participate as atherosclerotic factors affecting platelet hyperactivity, hypercoagulability, and hypofibrinolysis [@bib5], [@bib6], [@bib20].

TXA~2,~ a metabolite of arachidonic acid, is well known to regulate platelet aggregation and vasomotor response along with nitric oxide [@bib22]. Endothelial cells secrete nitric oxide which inhibits clot formation through vasodilation, by inhibiting the production of TXA~2~ [@bib23]. In addition, ADP and serotonin, in combination with thrombin, act as major mediators in the initiation of platelet recruitment and adhesion/activation, which are critical for blood coagulation [@bib24]. Fibrinogen not only promotes arterial and venous thrombosis via increased fibrin formation, platelet aggregation, and plasma viscosity, but also increases progressively with the severity of atherosclerosis [@bib5]. In our study, we found that the serum levels of TXA~2~ and serotonin in the GBx groups decreased significantly compared with the CON and HFD groups. In addition, the GBx 100 and 150 treatment groups showed significantly higher serum FDP concentrations than those of the other groups. These data suggest the possibility that GBx is involved in the regulation of blood flow.

PT is related to the extrinsic clotting pathway and aPTT is used to assess the intrinsic coagulation phase in plasma [@bib22]. These factors can serve as important risk factors in cardiovascular disease and as independent indicators of the progression of atherosclerosis [@bib25]. Therefore, PT and aPTT are the most widely used measures to investigate coagulation abnormalities [@bib26]. To examine the possibility of GBx as an antithrombotic agent, we investigated the effects of GBx on the coagulation cascade, using the classical coagulation assays (PT and aPTT content). Such coagulation assays with GB extract in animal models have not previously been reported. In the present study, we found that the PT values increased significantly in all GBx-treated groups, and aPTT levels increased when compared with the HFD group. These findings suggest that GBx contributes to the amelioration of blood flow by regulating the extrinsic clotting pathway. Moreover, the ability of ginseng to inhibit platelet aggregation was recently demonstrated in a separate study [@bib27]. Several other studies also reported that red ginseng inhibits platelet aggregation directly via nuclear factor-κB and mitogen-activated protein kinase signaling pathways [@bib8], [@bib11], [@bib28]. Collectively with previously reported data, our findings suggest that GBx may exert an ameliorating effect on blood flow by modulating lipid metabolites.

Increased intima-media thickness is an important predictor of cardiovascular disease incidence [@bib29]. The first signs of atherosclerosis include lipid deposits, resulting in fatty streaks in the intima of systemic arteries. Advanced atherosclerotic lesions arise from these fatty streaks [@bib30]. Our results also demonstrated that a HFD induced severe hypertrophic changes in the aortic walls, formation of atherosclerotic plaques, as well as significant increases in the mean thicknesses of the total aortic wall, tunica intima, and tunica media, and in the areas of lipid deposits in the aortic walls and atherosclerotic plaques compared with the CON group. However, these dyslipidemia-related histomorphometric changes in the sclerotic aorta were significantly improved by treatment with 50 mg/kg, 100 mg/kg, and 150 mg/kg GBx in a dose-dependent manner. In addition, Jeong et al [@bib11] recently reported that Korean Red Ginseng extract alleviates atherosclerotic lesions through monocyte chemoattractant protein-1 and tumor necrosis factor-α suppression in apoE knockout mice. Kim et al [@bib6] also demonstrated in a hyperlipidemic mouse model that Korean GB extract suppresses atherosclerotic lesion development through the inhibition of atherogenic inflammatory gene expression. Taken together, these findings illustrate the effects of GBx on intima-media thickness and histomorphometric changes.

Therefore, these data imply that GBx contributes to improved blood flow by decreasing intima-media thickness via the regulation of blood coagulation factors related to lipid metabolites in rats fed a HFD. However, more systematic studies will be necessary to determine whether GBx is useful in preventing the development of atherosclerosis and improving blood flow. In particular, a hemodynamic study and the establishment of indexes of blood flow using serum biochemistry and its mechanisms are needed.
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![Experimental study design. The rats were selected randomly and assigned to five groups. One group served as the control and was fed a normal diet (ND). The other four groups were fed a high-fat diet (HFD) containing 45% kcal from fat for 11 wk without ginseng berry (GB). Three of the HFD groups were additionally treated by gastric gavage with ginseng berry hot water extract (GBx) dissolved in distilled water at 50 (GBx 50) mg/kg, 100 (GBx 100) mg/kg, and 150 (GBx 150) mg/kg body weight for 6 wk.](gr1){#fig1}

![High-performance liquid chromatography analysis of the ginsenoside Re in the ginseng berry extract powder. The major ginsenosides of the ginseng berry hot water extract were analyzed using high-performance liquid chromatography.](gr2){#fig2}

![Liver histopathological images in the control group (A), high-fat diet (HFD) group (B), and groups treated with ginseng berry extract 50 mg/kg (C), 100 mg/kg (D), or 150 mg/kg (E) body weight together with a HFD. To examine hepatic histopathological changes in the control group, HFD, and groups treated with ginseng berry extract 50 mg/kg, 100 mg/kg, or 150 mg/kg body weight together with a HFD, Hematoxylin and Eosin and Oil red staining were performed as described in the Materials and methods section. CV, central vein; PT, potral triad.](gr3){#fig3}

![Aortic histopathological images in the control group (A), high-fat diet (HFD) group (B), and groups treated with ginseng berry extract 50 mg/kg (C), 100 mg/kg (D), or 150 mg/kg (E) body weight together with a HFD. To examine aortic histopathological changes in the control group, HFD, and groups treated with ginseng berry extract 50 mg/kg, 100 mg/kg, or 150 mg/kg body weight together with a HFD, Hematoxylin and Eosin and Oil red staining were performed as described in the Materials and methods section. LU, Lumen.](gr4){#fig4}

###### 

Effect of ginseng berry extract (GBx) supplementation on serum biochemical values in rats fed a high-fat diet

  ------------------------------------------------------------------------------------------------------------------------------
                 CON               HFD                HFD supplemented with                          
  -------------- ----------------- ------------------ ----------------------- ---------------------- ---------------------------
  Leptin\        55.20 ± 5.92      83.79 ± 3.16\*     75.10 ± 3.71\*          63.07 ± 10.31\*\*      66.27 ± 3.91\*\*
  (ng/mL)                                                                                            

  Apo E\         1111.89 ± 54.50   848.38 ± 51.52\*   1081.36 ± 106.24        1281.21 ± 125.05\*\*   1705.50 ± 170.62\*^,^\*\*
  (ng/mL)                                                                                            

  Apo B/A\       0.77 ± 0.03       0.83 ± 0.06        0.50 ± 0.02\*^,^\*\*    0.57 ± 0.03\*^,^\*\*   0.51 ± 0.02\*^,^\*\*
  (ng/mL)                                                                                            

  Adiponectin\   704.42 ± 50.94    138.59 ± 34.19\*   510.05 ± 31.89\*\*      530.70 ± 60.78\*\*     578.73 ± 71.38\*\*
  (ng/mL)                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------

Values are reported as the means ± standard deviation.

\* *p* \< 0.05 vs. CON group.

\*\* *p* \< 0.05 vs. HFD group.

Apo, apolipoprotein; CON, control group; GBx 50, 100, 150, groups treated with GB extract 50 mg/kg, 100 mg/kg, or 150 mg/kg body weight together with a HFD; HFD, high-fat diet group.

###### 

Effect of ginseng berry extract (GBx) supplementation on blood coagulation in rats fed high fat diet

                      CON              HFD                HFD supplemented with                              
  ------------------- ---------------- ------------------ ----------------------- -------------------------- --------------------------
  PT (s)              17.75 ± 0.74     15.66 ± 1.05\*     16.52 ± 0.60\*^,^\*\*   16.75 ± 0.89\*^,^\*\*      16.65 ± 0.52\*^,^\*\*
  aPTT (s)            17.62 ± 0.09     17.88 ± 0.47       17.99 ± 0.59            18.70 ± 0.87\*^,^\*\*      18.43 ± 1.09\*
  Col/EPI (s)         300.00 ± 0.00    289.70 ± 2.57      300.00 ± 0.00           300.00 ± 0.00              289.05 ± 4.15
  Col/ADP (s)         260.33 ± 1.40    263.80 ± 9.03      300.00 ± 0.00           298.80 ± 3.79              293.33 ± 8.73
  TXA~2~ (pg/mL)      295.87 ± 55.32   520.12 ± 25.12\*   459.61 ± 80.55\*        81.06 ± 10.48\*^,^\*\*     73.60 ± 10.36\*^,^\*\*
  Serotonin (pg/mL)   108.43 ± 16.55   126.63 ± 10.93     116.12 ± 15.85          95.08 ± 5.38               64.85 ± 10.96\*^,^\*\*
  FDP (pg/mL)         574.29 ± 35.36   554.01 ± 52.55     667.23 ± 48.18          1182.36 ± 92.31\*^,^\*\*   1053.94 ± 94.81\*^,^\*\*

Values are reported as the means ± standard deviation.

\* *p* \< 0.05 versus CON group.

\*\* *p* \< 0.05 versus HFD group.

aPTT, activated partial thromboplastin time; Col/ADP, collagen/adenosine-5-diphosphate; Col/EPI, collagen/epinephrine; CON, control group; FDP, fibrinogen degradation products; GBx 50, 100, 150, groups treated with GB extract 50 mg/kg, 100 mg/kg, or 150 mg/kg body weight together with a HFD; HFD, high-fat diet group; PT, prothrombin time; TXA~2~, thromboxane A~2~.

###### 

Histomorphometrical analysis of aorta tissues in rats fed high fat diet

                                 CON             HFD                HFD supplemented with                               
  ------------------------------ --------------- ------------------ ------------------------- ------------------------- -------------------------
  Mean thicknesses (μm/vessel)                                                                                          
  Total walls                    91.57 ± 12.43   147.64 ± 15.32\*   125.22 ± 15.21\*^,^\*\*   107.95 ± 11.73\*^,^\*\*   105.40 ± 13.44\*^,^\*\*
  Tunica intima                  3.08 ± 0.63     19.68 ± 2.01\*     11.02 ± 1.48\*^,^\*\*     7.95 ± 1.19\*^,^\*\*      6.16 ± 1.25\*^,^\*\*
  Tunica media                   80.06 ± 14.64   114.98 ± 15.22\*   97.89 ± 12.88\*^,^\*\*    88.88 ± 12.50\*           86.50 ± 8.47\*\*
  Region percentages (%)                                                                                                
  Atherosclerotic plaque         0.71 ± 0.32     30.35 ± 11.85\*    18.92 ± 7.75\*^,^\*\*     8.40 ± 2.17\*^,^\*\*      4.84 ± 2.00\*^,^\*\*
  Lipids                         1.31 ± 0.95     16.82 ± 3.92\*     12.73 ± 3.51\*^,^\*\*     8.47 ± 2.11\*^,^\*\*      4.34 ± 1.54\*^,^\*\*

Values are reported as the means ± standard deviation.

\* *p* \< 0.05 versus CON group.

\*\* *p* \< 0.05 versus HFD group.

CON, control group; GB, ginseng berry; GBx 50, 100, 150, groups treated with GB extract 50 mg/kg, 100 mg/kg, or 150 mg/kg body weight together with a HFD; HFD, high-fat diet group.
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